Canagliflozin, Dapagliflozin Warnings Strengthened by FDACanagliflozin, Dapagliflozin Warnings Strengthened by FDA

The FDA has strengthened its drug label warnings about the risk for acute kidney injury in patients taking canagliflozin or dapagliflozin for type 2 diabetes. News Alerts
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news